These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
365 related items for PubMed ID: 26224765
1. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial. Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M. Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765 [Abstract] [Full Text] [Related]
7. The MARLINA-T2D trial: putting the results into clinical perspective. Lajara R. Expert Rev Endocrinol Metab; 2018 May; 13(3):173-176. PubMed ID: 30058901 [Abstract] [Full Text] [Related]
8. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA. Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698 [Abstract] [Full Text] [Related]
10. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Diabetes Care; 2013 Nov; 36(11):3460-8. PubMed ID: 24026560 [Abstract] [Full Text] [Related]
15. Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes. Klein T, Tammen H, Mark M, Benetti E, Delić D, Schepers C, von Eynatten M. Diabetes Obes Metab; 2021 Aug; 23(8):1968-1972. PubMed ID: 33881796 [Abstract] [Full Text] [Related]
17. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria. Cooper ME, Perkovic V, Groop PH, Hocher B, Hehnke U, Meinicke T, Koitka-Weber A, van der Walt S, von Eynatten M. J Hypertens; 2019 Jun; 37(6):1294-1300. PubMed ID: 30540657 [Abstract] [Full Text] [Related]
20. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial. Cooper ME, Rosenstock J, Kadowaki T, Seino Y, Wanner C, Schnaidt S, Clark D, Johansen OE, CARMELINA investigators. Diabetes Obes Metab; 2020 Jul; 22(7):1062-1073. PubMed ID: 32037653 [Abstract] [Full Text] [Related] Page: [Next] [New Search]